International Edition
Latest News
Health

MUHC Launches First Study of Scalp-Cooling Device to Reduce Chemo Hair Loss

"Hair loss is always the number one worry for men and for women," Dr. Ramy Saleh said. The McGill University Health Centre has launched the first formal research study to measure how a new scalp-cooling device affects the…

MUHC Launches First Study of Scalp-Cooling Device to Reduce Chemo Hair Loss

“Hair loss is always the number one worry for men and for women,” Dr. Ramy Saleh said.

The McGill University Health Centre has launched the first formal research study to measure how a new scalp-cooling device affects the well-being of chemotherapy patients, La Presse reported, according to Lejournaldejoliette. The FEEL-CUSM trial, led by Saleh at the Cedars Cancer Centre, will enroll 100 patients aged 18 to 40 using four Paxman machines loaned by the manufacturer for one year, according to Lapresse.

Current scalp-cooling systems can cost a breast-cancer patient up to $10,000 out of pocket because Quebec’s public plan covers only drugs, not non-pharmacological cancer treatments, Saleh told La Presse. Each Paxman unit costs roughly $100,000 US, but the company agreed to lend the devices to the MUHC at no charge for the study period.

“We really have nothing that is covered by the government to reduce hair loss,” Saleh said. He added that if the government places a bulk order to equip each cancer centre with several devices, “they will save a lot of money.”

MUHC Launches First Study of Scalp-Cooling Device to Reduce Chemo Hair Loss
Photo: noovo.info

Cooling the scalp reduces blood flow to hair follicles, limiting the amount of chemotherapy drugs that reach them. Saleh said the Paxman system is designed to be simpler and less expensive than earlier machines because it can serve multiple patients on site, improving the return on investment for hospitals. He described the devices as markedly simpler and more user-friendly than previous technology.

“A woman of 30 who loses her hair on top of losing a breast will not really be accepted by society… She will have lost a part of her femininity and society will judge her,” Saleh said, describing the compounded trauma of mastectomy and alopecia in an era of social-media scrutiny.

“We are in a society that is very TikTok and Instagram,” he said. He estimated up to half of all cancer patients could eventually need access to cooling devices. Saleh said that while pharmacological advances now manage chemotherapy side effects such as nausea and vomiting effectively, medicine still lacks drug solutions to counteract hair loss.

The McGill University Health Centre, one of Montreal’s two major healthcare networks, was formed in 1997 through the voluntary merger of five teaching hospitals, including the Montreal General Hospital founded in 1821 and the Royal Victoria Hospital founded in 1893.

Its research institute, created the same year, now runs more than 1,600 projects with collaborators in 85 countries. The Cedars Cancer Centre, where the scalp-cooling trial is taking place, moved to the MUHC’s Glen site when it opened in 2015, consolidating adult, pediatric and cancer services in one location.

Saleh plans to present efficacy and quality-of-life data to the Quebec government within a year to argue for public funding. "I want to prove to the government that by having the technology in front of us and trying it on patients, patients will be happier, more comfortable with treatments, and will experience less anguish, less anxiety and less stress," he said.

About the author: Health Desk

Health Desk at Archynewsy.